Plasmodium Falciparum Clinical Trial
Official title:
Prevalence Survey of Plasmodium Falciparum Antimalarial Drug Resistance Markers at Sites in India
This is a cross-sectional, observational study using dried blood samples collected from P.
falciparum-infected individuals at the time of malaria diagnosis to measure the prevalence of
known and candidate molecular markers of resistance to artemisinin and non-artemisinin ACT
partner drugs. A maximum of 200 participants will be enrolled at each participating sites per
year. Study duration is 1 years. Therefore total participant is up to 400.
Prospective participants will have blood collected for dried blood spot (DBS) study sample
after providing informed consent. Individuals with confirmed P. falciparum infection will
have DBS samples included for molecular analyses for known and candidate molecular markers of
antimalarial drug resistance.
n/a
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Completed |
NCT01935882 -
Low Dose Primaquine for Clearance of Gametocytes
|
Phase 2/Phase 3 | |
| Completed |
NCT01775592 -
Plasmodium Falciparum Artemisinin Resistance Vietnam
|
Phase 4 | |
| Completed |
NCT01728701 -
Controlled Human Malaria Infection (CHMI) After Immunization With Cryopreserved Plasmodium Falciparum Sporozoites Under Chloroquine Prophylaxis
|
Phase 1 | |
| Completed |
NCT00914225 -
Effect of Bednets and a Water Purification Device on HIV Disease Progression Among ART naïve Patients in Kenya
|
N/A | |
| Completed |
NCT02895568 -
Prevalence Survey of Plasmodium Falciparum Antimalarial Drug Resistance Markers
|
||
| Completed |
NCT02259426 -
Dihydroartemisinin-piperaquine With Low Dose Primaquine to Reduce Malaria Transmission
|
Phase 3 | |
| Completed |
NCT01465048 -
Optimisation of Controlled Human Malaria Infection Using Sporozoites Administered by Needle and Syringe
|
N/A | |
| Completed |
NCT00392015 -
NMRC-M3V-Ad-PfCA Vaccine - Clinical Trial 1
|
Phase 1/Phase 2 | |
| Completed |
NCT04661579 -
RTS,S/AS01E Hypo-immuno-responsiveness Study
|
Phase 2 | |
| Recruiting |
NCT05400746 -
A Study of the Plasmodium Falciparum Malaria Vaccine Candidate Pfs48/45 in Matrix-M Adjuvant in the UK
|
Early Phase 1 | |
| Completed |
NCT03138096 -
Safety and Protective Efficacy of Pb(PfCS@UIS4)
|
Phase 1/Phase 2 | |
| Completed |
NCT03452475 -
Comparison of Arterolane-piperaquine Versus Arterolane-piperaquine+Mefloquine Versus Artemether-lumefantrine in Kenyan Children
|
Phase 3 | |
| Completed |
NCT00295581 -
PpPfs25/ISA51 and ScPvs25/ISA51 Vaccines for Malaria
|
Phase 1 | |
| Withdrawn |
NCT04203186 -
A Clinical Trial to Evaluate Plasmodium Falciparum 7G8 and NF54 Challenge Strains (PfSPZ) in a Head-to-head Comparative Study - (ECG-CHMI)
|
N/A | |
| Completed |
NCT02418962 -
Safety and Immunogenicity of Direct Venous Inoculation of a Radiation-attenuated PfSPZ Vaccine in Equatoguinean Adults
|
Phase 1 | |
| Completed |
NCT01160562 -
Pilot Study to Estimate the Burden and Distribution of Plasmodium Falciparum Malaria in Kalifabougou, Mali in Preparation for a Prospective Cohort Study of Naturally-Acquired Malaria Immunity
|
||
| Terminated |
NCT04445103 -
The Malaria Heart Disease Study
|
||
| Completed |
NCT03132402 -
ELISA Validation of Hypersensitive Rapid Diagnostic Test Results for Detection of P. Falciparum
|
||
| Completed |
NCT03172221 -
Clinical Performance of the HRP2 HS-RDT for Malaria Diagnosis in Pregnant Women
|
||
| Completed |
NCT02090036 -
Efficacy and Safety of a Single Low-dose Primaquine for the Clearance of Gametocytes
|
Phase 4 |